ONWARD ONWARD ONWARD

ONWARD

Neuromodulation technologies for spinal cord injury patients

ONWARD develops Targeted Epidural Spinal Stimulation (TESS), an implantable  neurostimulator for patients with spinal cord injury. The company’s device supports motor function recovery for better and faster rehabilitation by stimulating the spinal cord. Onward is developing two technology platforms, ARCEX and ARCIM, for which the FDA has granted nine Breakthrough Device Designations. The company realized an IPO on Euronext in 2021.

Life Sciences
Visit website

Investment 
details

Entry

Staff

110

Location

Netherlands

The support and guidance provided by Gimv has been instrumental in our effort to create breakthrough technologies that improve the lives of people living with spinal cord injury.

Dave Marver

CEO

header Onward
Partnership Gimv Partnership Gimv Partnership Gimv

Partnership Gimv

From the start, Gimv is convinced that Onward is one of the most promising companies in the emerging field of neurostimulation. Gimv is fortunate to enjoy strong relationships with many of the leading organisations that support research and innovation for individuals and families impacted by paralysis, and we admire and celebrate the grit, courage, and determination shown daily by those we hope to serve.

News News News

News

Portfolio

ONWARD Completes $32 Million Financing Round

Portfolio

2020 06 19 - GTX announces FDA Breakthrough Device Designation

Portfolio

GTX medical BV and NeuroRecovery Technologies Inc. Merge to Create Leading Neurostimulation Company for Spinal Cord Injury

See all news articles